AccessPak for HIV PEP Basic and Ixiaro

• Generic Name: emtricitabine / tenofovir
• Dosage Forms: n.a.
• Other Brand Names: AccessPak for HIV PEP Basic, Descovy, Truvada

AccessPak for HIV PEP Basic are antiviral medicines that prevent human immunodeficiency virus (HIV) from multiplying in your body.

AccessPak for HIV PEP Basic is a combination medicine used to treat HIV, the virus that can cause acquired immunodeficiency syndrome (AIDS). AccessPak for HIV PEP Basic is not a cure for HIV or AIDS, but it can be used to treat HIV in adults and children who are at least 12 years old and weigh at least 17 kilograms (37 pounds).

AccessPak for HIV PEP Basic is also used in children who weigh between 55 and 77 pounds (25 to 35 kilograms) and who take certain other HIV medications.

Truvada PrEP is used together with safer-sex practices to reduce the risk of becoming infected with HIV. You must be HIV-negative and an adult to use Truvada PrEP for this purpose.

AccessPak for HIV PEP Basic may also be used for purposes not listed in this medication guide.

• Generic Name: japanese enceph vacc sa14-14-2, inactivated
• Dosage Forms: n.a.
• Other Brand Names: Ixiaro

Ixiaro vaccine is used to help prevent Japanese encephalitis in adults and adolescents who are at least 17 years old.

Japanese encephalitis is a serious disease caused by a virus. It is the leading cause of viral encephalitis (inflammation of the brain) in Asia. Encephalitis is an infection of the membrane around the brain and spinal cord. This infection often causes only mild symptoms, but prolonged swelling of the brain can cause permanent brain damage or death.

Japanese encephalitis virus is carried and spread by mosquitoes.

Ixiaro vaccine works by exposing you to a small dose of the virus, which causes the body to develop immunity to the disease. Ixiaro vaccine will not treat an active infection that has already developed in the body.

Ixiaro vaccine is recommended for people who live in or travel to areas where Japanese encephalitis is known to exist, or where an epidemic has recently occurred.

You should receive the Ixiaro vaccine and booster dose at least 1 week prior to your arrival in an area where you may be exposed to the virus.

Not everyone who travels to Asia needs to receive an Ixiaro vaccine. Follow your doctor instructions or the recommendations of the Centers for Disease Control and Prevention (CDC).

Ixiaro vaccine is also recommended for people who work in a research laboratory and may be exposed to Japanese encephalitis virus through needle-stick accidents or inhalation of viral droplets in the air.

Like any vaccine, the Ixiaro vaccine may not provide protection from disease in every person.